Bacterial Infections Clinical Trial
Official title:
The Impact of Preauthorization Compared to Prospective Audit on Outcome Indicators as Core Strategies of Antimicrobial Stewardship Program
Antimicrobial stewardship program (ASP) is recommended to improve appropriate antimicrobial use, reduce bacterial resistance, unnecessary drug costs and enhance patient health outcomes. Two core strategies of ASP recommended as effective in guidelines are formulary restriction with drug preauthorization and prospective audit with feedback. Investigators will evaluate the effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes.
Background: Antimicrobial stewardship program (ASP) is recommended to improve appropriate
antimicrobial use, reduce bacterial resistance, unnecessary drug costs and enhance patient
health outcomes. Two core strategies of ASP recommended as effective in guidelines are
formulary restriction with drug preauthorization and prospective audit with feedback.
Preauthorization is the current strategy used in our hospital, while most other hospitals in
Taiwan and worldwide uses prospective audit with feedback. Preauthorization requires
intensive manpower to maintain timeliness of antimicrobial use. This study will evaluate a
policy change in strategy used for antimicrobial stewardship. Investigators will evaluate
the effectiveness of the 2 strategies using antimicrobial utilization and patient outcomes.
Methods: During a stepwise change in the policy of the antimicrobial stewardship program in
this hospital, the study will observe the differences between two standardized core
strategies (preauthorization vs prospective audit) of ASP. Hospitalized patients aged 20 and
above, requiring use of restricted antimicrobials will be recruited into the study. Signing
of consent forms are waived since both strategies are already proven to be effective and are
widely implemented in Taiwan and worldwide. Also, the evaluation of such policy changes will
not impact on patient safety or patient rights. The conduction of the study will not require
contacting patients and no clinical samples will be collected. All data required for
analysis will be collected via a computerized patient care system. Patient data will be
protected via de-linking. Patients will be excluded if admitted at or entered the intensive
care unit within 48 hours of entry, and if infectious diseases consultation had been
requested. Eligible patients will be randomized to either preauthorization, which is the
current practice in the hospital; or prospective audit, that will be done at 48-72 hours
after prescription, as is the current practice in other hospitals in Taiwan and worldwide.
Managing physicians are not obligated to follow our advice and the investigators will not
intervene in their management decisions. Primary outcomes include antimicrobial utilization,
drug costs and patient outcomes such as length of stay and clinical improvement. The time
spent on implementing these two strategies will be compared.
The study hypothesis is that the preauthorization group will impact on a reduction in
antimicrobial cost and utilization, especially in the first 72 hours, when compared to
prospective audit. However, patient outcomes will likely be similar. Antimicrobial
stewardship programs using preauthorization as a core strategy compared to prospective audit
with feedback have similar patient outcomes, but may reduce antimicrobial utilization.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
| Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
| Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
| Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
| Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
| Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
| Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
| Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
| Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
| Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
| Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
| Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
| Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
| Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
| Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
| Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
| Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
| Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |